Justin Levisay
Interventional Cardiology · Evanston, ILNPI 1255458055
Payments from drug & device makers
Across 525 payments — averaging $1594.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$644K
- Edwards Lifesciences$119K
- Abiomed$50K
- Heartflow, Inc.$10K
- Abbott$7K
- Medtronic$4K
- plus $4K from 23 others
Across 4 payments — averaging $161.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$645
What the payments were for
- Consulting fees$16,71316%
- Speaking & faculty fees$64,97561%
- Travel & lodging$7,3657%
- Food & beverage$17,00216%
- Education$170%
- Gifts$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 197 | $643,794 |
| Edwards Lifesciences | 62 | $118,810 |
| Abiomed | 57 | $50,156 |
| Heartflow, Inc. | 13 | $9,542 |
| Abbott | 45 | $6,831 |
| Medtronic(2 entities) | 42 | $3,643 |
| Siemens Medical Solutions USA, Inc. | 19 | $1,698 |
| Biotronik Inc. | 4 | $349 |
| Philips North America LLC | 4 | $333 |
| Johnson & Johnson | 12 | $325 |
| Pfizer | 9 | $228 |
| Shockwave Medical, Inc | 2 | $224 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $203 |
| E.r. Squibb & Sons, L.L.C. | 10 | $202 |
| ZOLL Circulation Inc | 1 | $150 |
| Opsens Inc. | 7 | $147 |
| Novartis | 7 | $144 |
| Boehringer Ingelheim | 3 | $81 |
| Teleflex LLC | 3 | $68 |
| Amgen | 3 | $54 |
| GE HealthCare | 1 | $45 |
| Inari Medical, Inc. | 2 | $40 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $33 |
| Biosense Webster, Inc. | 1 | $32 |
| Novo Nordisk | 1 | $24 |
| Terumo Medical Corporation | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Cvrx, Inc. | 1 | $16 |
| Cardiovascular Systems Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$22,809
- GENERAL - STRUCTURAL HEART$15,920
- GENERAL - THERAPIES$13,105
- FFRct$9,391
- GENERAL VASCULAR ACCESS$2,500
- CoreValve Evolut$2,377
- AVVIGO Guidance System$1,726
- EVOQUE$1,414
- Mitra Clip system$1,399
- Edwards SAPIEN 3 Transcatheter Heart Valve$920
- LOTUS EDGE$588
- NAVITOR$525
- CorPath Imaging System$506
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$426
- SAPIEN 3 Ultra RESILIA$300
- COREVALVE EVOLUT R$290
- MitraClip System$260
- PASCAL$260
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$212
- 3F$162
How this compares
$837,219 in reported general payments places this provider in the 95th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 107 | $93,914 |
| Repatha SureclickEvolocumab | 29 | $42,362 |
| EntrestoSacubitril/Valsartan | 20 | $26,603 |
| OzempicSemaglutide | 11 | $17,040 |
| BrilintaTicagrelor | 23 | $13,784 |
| Repatha SyringeEvolocumab | 17 | $13,152 |
| Prasugrel Hcl | 96 | $5,227 |
| ClopidogrelClopidogrel Bisulfate | 399 | $4,639 |
| Carbamazepine ErCarbamazepine | 22 | $1,976 |
| Metoprolol Succinate | 118 | $1,615 |
| Rosuvastatin Calcium | 111 | $1,536 |
| Atorvastatin Calcium | 183 | $1,513 |
| Ezetimibe | 54 | $1,187 |
| Carvedilol | 73 | $997 |
| Amlodipine Besylate | 63 | $641 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $228 | $93,914107 claims |
| NovartisEntresto | $144 | $26,60320 claims |
| Novo NordiskOzempic | $24 | $17,04011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Evanston
- Mark RicciardiEvanston$2.2M
- Ted FeldmanEvanston$376K
- Jonathan RosenbergEvanston$61K
- Charles DavidsonChicago$5.8M
- Ravi RamanaPalos Park$2.8M
- Andrei PopElk Grove Village$1.9M
- Krishna Rocha SinghSpringfield$1.7M
- Bruce LewisMaywood$1.3M
- Atman ShahChicago$794K
- Laura DavidsonChicago$661K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.